Evidence available on 21 September 2026
The 21 September discovery record contains material using Spike 500 Amrix, a reordered name, and existing network coverage. No primary document established equivalence or a holding-cost schedule for Spike Amrix 500. That prevents the review from importing charges or account conditions from the near-name material. It also prevents treating previous articles' unsupported regulator-search assertions as findings of this investigation.
A holding-period calculation needs the exact offer
If a specific proposal includes a position that can remain open, ask for a calculation over two defined holding periods with the same initial assumptions. The quotation should separate price movement from any scheduled charges and explain the dates used. This is a hypothetical comparison to request, not a claim that Spike Amrix 500 offers such positions or imposes an overnight fee. A starting-price headline would not answer the question.
Evidence needed for a measured assessment
A useful future record would identify the provider, instrument, currency and terms behind both calculations. Only then could their differences be interpreted. We have not obtained that evidence, funded an account or measured a holding cost. The exact-name product remains unknown, and no number in the brand is interpreted as a price, leverage ratio or capacity. The spelling distinction remains open until an attributable source resolves it.
